Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s Why

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down prior to trading on Tuesday . The stock had previously closed at $46.3750, but opened at $43.1050. Zealand Pharma A/S shares last traded at $43.1050, with a volume of 103 shares changing hands.

Wall Street Analyst Weigh In

ZLDPF has been the topic of several research analyst reports. Barclays lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zealand Pharma A/S presently has an average rating of “Hold”.

Zealand Pharma A/S Stock Up 0.2%

The firm has a 50-day simple moving average of $47.25 and a 200 day simple moving average of $46.51. The stock has a market capitalization of $3.08 billion, a P/E ratio of 7.15 and a beta of 0.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes.